| Literature DB >> 28131995 |
N Boffin1, S Moreels1, J Deblonde2, V Van Casteren1.
Abstract
OBJECTIVES: To describe and explore data from the surveillance of chlamydia, syphilis, gonorrhoea and genital warts by the Belgian Network of Sentinel General Practices (SGP) over the first 2 years (2013 and 2014) and to estimate the incidence of these 4 sexually transmitted infections (STIs). A special focus is put on data quality.Entities:
Keywords: Belgium; PRIMARY CARE; PUBLIC HEALTH; sexually transmitted infections; surveillance data
Mesh:
Year: 2017 PMID: 28131995 PMCID: PMC5278247 DOI: 10.1136/bmjopen-2016-012118
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of new episodes of patients with STI reported by the SGP in 2013–2014 (N=306)
| Row % (95% CI) | Total | ||
|---|---|---|---|
| 2013 | 2014 | n (%) | |
| Gender (valid n=279) | |||
| Men | 56.1 (43.6 to 71.0) | 58.3 (47.0 to 71.6) | 160 (57.3) |
| Women | 43.9 (33.0 to 57.3) | 41.7 (32.2 to 53.1) | 119 (42.7) |
| | |||
| Age in years (valid n=295) | |||
| <25 | 38.5 (28.8 to 50.5) | 37.5 (28.6 to 48.3) | 112 (38.0) |
| 25–44 | 48.1 (37.2 to 61.4) | 49.4 (39.1 to 61.5) | 144 (48.8) |
| ≥45 | 13.3 (7.9 to 21.1) | 13.1 (8.1 to 20.1) | 39 (13.2) |
| | |||
| Educational level (valid n=210) | |||
| Primary or lower | 6.9 (2.8 to 14.3) | 1.8 (0.2 to 6.6) | 9 (4.3) |
| Secondary | 47.5 (35.0 to 63.0) | 56.9 (43.6 to 72.9) | 110 (52.4) |
| Tertiary or higher | 45.5 (33.3 to 60.8) | 41.3 (30.1 to 55.2) | 91 (43.3) |
| | |||
| Country of birth (valid n=295) | |||
| Belgium | 85.2 (70.3 to 1.00) | 80.6 (67.3 to 95.8) | 244 (82.7) |
| Other country | 14.8 (9.0 to 22.9) | 19.4 (13.2 to 27.5) | 51 (17.3) |
| | |||
| STI diagnoses (valid n=306) | |||
| Chlamydia | 36.7 (27.3 to 48.2) | 48.5 (38.5 to 60.3) | 132 (43.1) |
| Gonorrhoea | 20.1 (13.4 to 29.1) | 14.4 (9.2 to 21.4) | 52 (17.0) |
| Syphilis | 12.2 (7.1 to 19.6) | 8.4 (4.6 to 14.1) | 31 (10.1) |
| Genital warts | 28.1 (20.0 to 38.4) | 21.0 (14.6 to 29.1) | 74 (24.2) |
| Co-infection | 2.9 (0.8 to 7.4) | 7.8 (4.1 to 13.3) | 17 (5.6) |
| | |||
| Reinfection (valid n=306) | 12.9 (7.7 to 20.5) | 17.4 (11.6 to 24.9) | 47 (15.4) |
| | |||
| RFE or STI-related symptoms (valid n=300) | |||
| Screening (patient-initiated) | 16.9 (10.7 to 25.4) | 22.6 (15.9 to 31.1) | 60 (20.0) |
| Prenatal STI test | 2.9 (0.8 to 7.5) | 1.2 (0.0 to 4.4) | 6 (2.0) |
| Partner with STI | 12.5 (7.3 to 20.0) | 15.9 (10.4 to 23.2) | 43 (14.3) |
| Other RFE (non-symptom-based) | 9.6 (5.1 to 16.3) | 6.1 (2.9 to 11.2) | 23 (7.7) |
| | 41.2 (31.1 to 53.5) | 45.7 (36.0 to 57.3) | 131 (43.7) |
| Urethritis/epididymitis | 29.4 (21.0 to 40.0) | 29.9 (22.1 to 39.5) | 89 (29.7) |
| Proctitis | 0.3 (0.0 to 7.5) | 0.6 (0.0 to 3.4) | 5 (1.7) |
| Cervicitis/vaginitis | 12.5 (7.3 to 20.0) | 10.4 (6.0 to 16.6) | 34 (11.3) |
| Genital ulcer | 8.1 (4.0 to 14.5) | 5.5 (2.5 to 10.4) | 20 (6.7) |
| Other symptoms | 19.1 (12.5 to 28.0) | 22.0 (15.4 to 30.4) | 62 (20.7) |
| | 67.6 (54.5 to 83.0) | 62.8 (51.3 to 76.2) | 195 (65.0) |
| | |||
| Sexual risk history | |||
| Infection acquired abroad (valid n=293) | 6.1 (2.6 to 12.0) | 8.0 (4.3 to 13.7) | 21 (7.2) |
| | |||
| Homosexual or bisexual contacts (valid n=278) | 20.5 (13.4 to 30.0) | 12.6 (7.6 to 19.6) | 45 (16.2) |
| | |||
| ≥2 sex partners in last 6 months (valid n=191) | 36.0 (24.6 to 50.8) | 40.2 (28.8 to 54.5) | 73 (38.2) |
| | |||
| No condom use (valid n=229) | 80.6 (64.2 to 99.9) | 81.7 (66.7 to 99.1) | 186 (81.2) |
| | |||
| No steady relation (valid n=257) | 40.7 (30.0 to 53.9) | 46.8 (36.1 to 59.6) | 113 (44.0) |
| | |||
| (Contact with) SW (valid n=240) | 6.3 (2.5 to 13.0) | 7.0 (3.2 to 13.2) | 16 (6.7) |
| | |||
| (Contact with) drug injecting person (valid n=259) | 0.0 (−3.1)* | 3.6 (1.2 to 8.3) | 5 (1.9) |
| | |||
| Sexual risk score (0–7) (valid n=139) | |||
| ≥Median | 52.5 (35.9 to 74.1) | 51.3 (36.6 to 69.8) | 72 (51.8) |
| | |||
| HIV serologic status (valid n=287) | |||
| Never tested | 30.3 (21.6 to 41.3) | 35.5 (26.7 to 46.2) | 95 (33.1) |
| No results yet | 3.8 (1.2 to 8.8) | 5.8 (2.7 to 11.0) | 14 (4.9) |
| HIV negative | 61.3 (48.7 to 76.3) | 58.0 (46.7 to 71.4) | 171 (59.6) |
| HIV positive | 4.5 (1.7 to 9.9) | 6.5 (0.0 to 3.6) | 7 (2.4) |
| | |||
| Reason absence HIV test (valid n=65) | |||
| Refusal | 4.3 (0.0 to 24.2) | 9.5 (2.6 to 24.4) | 5 (7.7) |
| Not proposed by GP | 34.8 (15.0 to 68.5) | 57.1 (36.6 to 85.0) | 32 (49.2) |
| Test is planned | 60.9 (33.3 to 100) | 33.3 (18.2 to 56.0) | 28 (43.1) |
| | |||
| Discussion partner notification (valid n=287) | 87.1 (71.9 to 100) | 94.8 (80.1 to 100) | 226 (91.3) |
| | |||
| Region (valid n=306) | |||
| Flanders (vs Wallonia/Brussels) | 77.0 (63.1 to 93.0) | 75.4 (62.9 to 89.8) | 233 (76.1) |
| | |||
*One-sided 97.5% CI.
GP, general practitioner; RFE, reason for encounter; SGP, Belgian Network of Sentinel General Practices; STI, sexually transmitted infection; SW, sex worker.
Episode-based incidence of four STIs per 100 000 patients in the Belgian general practice population by (imputed) gender in 2013–2014
| All | Women | Men | |
|---|---|---|---|
| Chlamydia | 44.1 (37.3–51.9) | 50.7 (40.6–62.6) | 37.3 (28.5–47.9) |
| Genital warts | 24.0 (19.0–29.9) | 28.1 (20.6–37.5) | 20.0 (13.9–28.0) |
| Gonorrhoea | 18.9 (14.5–24.2) | ||
| Syphilis | 9.9 (6.8–13.9) | ||
| Any of four STIs | 91.9 (81.9–102.8) | 78.4 (65.7–92.9) | 105.8 (90.6–122.8) |
| Person-based STI incidence | 89.5 (79.6–100.2) | 77.8 (65.1–92.3) | 101.5 (86.7–118.2) |
STI, sexually transmitted infection.
Non-overlapping confidence intervals are in bold.
Episode-based incidence of gonorrhoea and syphilis per 100 000 general practice patients in Flanders (SGP data) compared with the incidence per 100 000 inhabitants in Flanders based on mandatory notification data in 2013–2014
| Gonorrhoea | Syphilis | |||
|---|---|---|---|---|
| SGP | Mandatory notification | SGP | Mandatory notification | |
| Women | 8.1 (3.7–15.5) | 8.3 (7.6–9.0) | 3.6 (1.0–9.3) | 2.1 (1.8–2.5) |
| Men | 36.2 (25.7–49.4) | 31.1 (29.7–32.5) | 18.5 (11.3–28.6) | 13.1 (12.2–14.0) |
SGP, Belgian Network of Sentinel General Practices.